RVPH250117C1000
- 1.10
- 0.000.00%
Reviva Pharmaceuticals Newsroom
Express News | Reviva Pharmaceuticals Option Alert: 1,491 Jul $2.50 Calls Swept Near Ask At $0.451 With 2.5K OI; Stock Trading Around $1.95
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit
Express News | Applied Therapeutics Inc - Shoshana Shendelman Steps Down as CEO
Express News | Applied Therapeutics Appoints John H. Johnson as Executive Chairman
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Sector Update: Health Care Stocks Ease Late Afternoon
Top Midday Decliners
Reviva Pharmaceuticals Shares Slide Premarket After Stock Offering
Reviva Pharmaceuticals 12M Share Spot Secondary Priced at $1.50
Reviva Pharm Holdings Prices Underwritten Public Offering of 12M Common Shares, Warrants at Combined Offering of $1.50 Per Share and Associated Warrant>RVPH
Reviva Pharm Holdings: Offering Expected to Close on or About Dec. 18 >RVPH
Reviva Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
Reviva Pharmaceuticals Reports Positive Topline Phase 3 Data on Brilaroxazine for Treating Schizophrenia
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
Reviva Announces Proposed Public Offering
8-K: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Reviva Pharmaceuticals Reports Q3 EPS (25c), Consensus (25c)
Reviva Pharmaceuticals Reports Progress on Brilaroxazine Trials and Financial Results for Q3 2024
Reviva Pharm Holdings 3Q Loss/Shr 25c >RVPH
Reviva Pharm Holdings Is Maintained at Buy by D. Boral Capital